Logo 1 Logo 2

Clinical Trial Details

Trial ID: L7284
Source ID: NCT00067951
Associated Drug: Rosiglitazone/Metformin
Title: A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: rosiglitazone/metformin
Outcome Measures: Primary: Hemoglobin A1c (HbA1c) reduction after 24 weeks of treatment. | Secondary: Change in FPG, insulin,C-peptide, insulin sensitivity,beta cell function, free fatty acids, lipids. Change in weight, vital signs, clinical laboratory tests, and adverse experiences.
Sponsor/Collaborators: Sponsor: GlaxoSmithKline
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 190
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2003-10-17
Completion Date: 2004-11-30
Results First Posted:
Last Update Posted: 2018-03-21
Locations: GSK Investigational Site, Anniston, Alabama, 36207, United States|GSK Investigational Site, Chandler, Arizona, 85224, United States|GSK Investigational Site, Phoenix, Arizona, 85014, United States|GSK Investigational Site, Phoenix, Arizona, 85050, United States|GSK Investigational Site, Tucson, Arizona, 85745, United States|GSK Investigational Site, Encinitas, California, 92024, United States|GSK Investigational Site, Fullerton, California, 92835, United States|GSK Investigational Site, Los Banos, California, 93635, United States|GSK Investigational Site, Mission Viejo, California, 92691, United States|GSK Investigational Site, Jacksonville, Florida, 32204, United States|GSK Investigational Site, Melbourne, Florida, 32901, United States|GSK Investigational Site, Miami, Florida, 33156, United States|GSK Investigational Site, Orlando, Florida, 32806, United States|GSK Investigational Site, Saint Cloud, Florida, 34769, United States|GSK Investigational Site, Atlanta, Georgia, 30308, United States|GSK Investigational Site, Atlanta, Georgia, 30342, United States|GSK Investigational Site, Fayetteville, Georgia, 30214, United States|GSK Investigational Site, Woodstock, Georgia, 30189, United States|GSK Investigational Site, Chicago, Illinois, 60607, United States|GSK Investigational Site, Evansville, Indiana, 47713, United States|GSK Investigational Site, Newburgh, Indiana, 47630, United States|GSK Investigational Site, Slidell, Louisiana, 70461, United States|GSK Investigational Site, Jackson, Mississippi, 39202, United States|GSK Investigational Site, Chesterfield, Missouri, 63017, United States|GSK Investigational Site, Kansas City, Missouri, 64111, United States|GSK Investigational Site, Saint Louis, Missouri, 63376, United States|GSK Investigational Site, Las Vegas, Nevada, 89103, United States|GSK Investigational Site, Kingston, New York, 12401, United States|GSK Investigational Site, New York, New York, 10024, United States|GSK Investigational Site, New York, New York, 10029, United States|GSK Investigational Site, New York, New York, 10032, United States|GSK Investigational Site, Rochester, New York, 14609, United States|GSK Investigational Site, Charlotte, North Carolina, 28210, United States|GSK Investigational Site, Mogadore, Ohio, 44260, United States|GSK Investigational Site, Downingtown, Pennsylvania, 19335, United States|GSK Investigational Site, Warminster, Pennsylvania, 18974, United States|GSK Investigational Site, West Chester, Pennsylvania, 19382, United States|GSK Investigational Site, Johnson City, Tennessee, 37601, United States|GSK Investigational Site, Arlington, Texas, 76017, United States|GSK Investigational Site, Beaumont, Texas, 77701, United States|GSK Investigational Site, Bryan, Texas, 77802, United States|GSK Investigational Site, Corpus Christi, Texas, 78411, United States|GSK Investigational Site, Dallas, Texas, 75230, United States|GSK Investigational Site, Midland, Texas, 79705, United States|GSK Investigational Site, San Antonio, Texas, 78221, United States|GSK Investigational Site, San Antonio, Texas, 78237, United States|GSK Investigational Site, Seattle, Washington, 98108, United States|GSK Investigational Site, Spokane, Washington, 99207, United States|GSK Investigational Site, Wenatchee, Washington, 98801, United States|GSK Investigational Site, Camperdown, New South Wales, 2050, Australia|GSK Investigational Site, St Leonards, New South Wales, 2065, Australia|GSK Investigational Site, Wollongong, New South Wales, 2500, Australia|GSK Investigational Site, Kippa Ring, Queensland, 4021, Australia|GSK Investigational Site, Woolloongabba, Queensland, 4102, Australia|GSK Investigational Site, North Adelaide, South Australia, 5006, Australia|GSK Investigational Site, Caulfield, Victoria, 3162, Australia|GSK Investigational Site, Fremantle, Western Australia, 6959, Australia|GSK Investigational Site, Perth, Western Australia, 6000, Australia|GSK Investigational Site, Calgary, Alberta, T3E 0C5, Canada|GSK Investigational Site, Coquitlam, British Columbia, V3K 3V9, Canada|GSK Investigational Site, Langley, British Columbia, V3A 4H9, Canada|GSK Investigational Site, Moncton, New Brunswick, E1G 1A7, Canada|GSK Investigational Site, Halifax, Nova Scotia, B3K 5R3, Canada|GSK Investigational Site, Brampton, Ontario, L6T 3T1, Canada|GSK Investigational Site, Burlington, Ontario, L7M 4Y1, Canada|GSK Investigational Site, Courtice, Ontario, L1E 3C3, Canada|GSK Investigational Site, Kitchener, Ontario, N2C 2N9, Canada|GSK Investigational Site, North Bay, Ontario, P1B 2H3, Canada|GSK Investigational Site, Oshawa, Ontario, L1H 1C2, Canada|GSK Investigational Site, Peterborough, Ontario, K9H 5G1, Canada|GSK Investigational Site, Peterborough, Ontario, K9J 7B3, Canada|GSK Investigational Site, Renfrew, Ontario, K7V 1P6, Canada|GSK Investigational Site, Stoney Creek, Ontario, L8G 2V6, Canada|GSK Investigational Site, Toronto, Ontario, M3J 1N2, Canada|GSK Investigational Site, Laval, Quebec, H7T 2P5, Canada|GSK Investigational Site, Montreal, Quebec, H1V 1X4, Canada|GSK Investigational Site, Montreal, Quebec, H3S 2W1, Canada|GSK Investigational Site, Montreal, Quebec, H4N 2W2, Canada|GSK Investigational Site, Plessisville, Quebec, G6L 3J1, Canada|GSK Investigational Site, Pointe-Claire, Quebec, H9R 4S3, Canada|GSK Investigational Site, Saint Insidore De Dorchester, Quebec, G0S 2S0, Canada|GSK Investigational Site, Saint Marc Des Carrieres, Quebec, G0A 4B0, Canada|GSK Investigational Site, Sainte Jerome, Quebec, J7Z 5T3, Canada|GSK Investigational Site, Sherbrooke, Quebec, J1H 1Z1, Canada|GSK Investigational Site, Regina, Saskatchewan, S4P 3X1, Canada|GSK Investigational Site, Saskatoon, Saskatchewan, S7K 0M5, Canada|GSK Investigational Site, Pusan, 602-739, Korea, Republic of|GSK Investigational Site, Seoul, 139-872, Korea, Republic of|GSK Investigational Site, Uijeongbu,, 480-821, Korea, Republic of|GSK Investigational Site, Auckland, 1311, New Zealand|GSK Investigational Site, Auckland, 1701, New Zealand|GSK Investigational Site, Christchurch, 8001, New Zealand|GSK Investigational Site, Rotorua, 3201, New Zealand|GSK Investigational Site, Wellington, 6035, New Zealand
URL: https://clinicaltrials.gov/show/NCT00067951

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D116 Rosiglitazone small molecule DB00412 Details
D089 Metformin small molecule DB00331 Details